| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JCEM.85.2.6393 |
| P698 | PubMed publication ID | 10690882 |
| P2093 | author name string | Bone HG | |
| Recker RR | |||
| Meunier PJ | |||
| Davidson M | |||
| Lombardi A | |||
| Weiss SR | |||
| Miller SS | |||
| Yates AJ | |||
| Greenspan SL | |||
| Downs RW | |||
| Emkey R | |||
| Suryawanshi S | |||
| Bell N | |||
| Mulloy AL | |||
| Heyden N | |||
| McKeever C | |||
| Musliner T | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 720-726 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group | |
| P478 | volume | 85 |
| Q34300668 | 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. |
| Q85276262 | A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women |
| Q34297505 | Alendronate: an update of its use in osteoporosis |
| Q37426686 | Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice |
| Q34986933 | Bisphosphonates and atypical fractures of femur |
| Q37145377 | Bone biopsy in patients with osteoporosis |
| Q45288270 | BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial |
| Q33689384 | Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women |
| Q36067698 | Combination therapy for osteoporosis: considerations and controversy |
| Q81515448 | Combination therapy for osteoporosis: considerations and controversy |
| Q36203344 | Combination/sequential therapy in osteoporosis |
| Q38167249 | Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis |
| Q37340331 | Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface |
| Q27026510 | Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents? |
| Q90315384 | Diagnosis of osteoporosis in statin-treated patients is dose-dependent |
| Q27021396 | Do bisphosphonates cause femoral insufficiency fractures? |
| Q33661422 | Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial. |
| Q46647307 | Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study |
| Q46679551 | Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats |
| Q44650878 | Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women |
| Q24289042 | Evidence based medicine: a movement in crisis? |
| Q36895366 | From space to Earth: advances in human physiology from 20 years of bed rest studies (1986-2006). |
| Q37430395 | Genetics of the bone response to bisphosphonate treatments |
| Q35903603 | Hormone replacement therapy and the prevention of postmenopausal osteoporosis |
| Q34359898 | Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis |
| Q35919125 | Management of age-related osteoporosis and prevention of associated fractures |
| Q34640851 | Mechanisms of bone loss and gain in untreated and treated osteoporosis |
| Q35901335 | Osteoporosis risk assessment and ethnicity: validation and comparison of 2 clinical risk stratification instruments |
| Q36888634 | Osteoporosis: prevention and treatment in anorexia nervosa |
| Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
| Q34019716 | Relationship among Bone Mineral Density Reduction, Hearing Loss, and Balance Disorders in Osteoporotic Patients |
| Q42728805 | Relationship between Bone Mineral Density and Balance Disorders in Osteoporotic Patients |
| Q35755138 | Relationship between bone mineral density, its associated physiological factors, and tooth loss in postmenopausal Korean women |
| Q48118668 | Single-dose local administration of parathyroid hormone (1-34, PTH) with β-tricalcium phosphate/collagen (β-TCP/COL) enhances bone defect healing in ovariectomized rats. |
| Q37565221 | Soy isoflavone: The multipurpose phytochemical (Review). |
| Q33896122 | The effect of antiresorptives on bone quality |
| Q87719696 | The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats |
| Q37950921 | The use of combination therapy in the treatment of postmenopausal osteoporosis |
| Q36203243 | Use of highly potent bisphosphonates in the treatment of osteoporosis |
| Q39408210 | Using Osteoporosis Therapies in Combination |
Search more.